menu
    • menu
    [{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laekna Therapeutics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"FAZ053","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laekna Therapeutics \/ Laekna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laekna Therapeutics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase III","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"14-C Afuresertib","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase III","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Afuresertib","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Laekna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAE005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAE120","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Laekna Therapeutics

    Menu

    Laekna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE102

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : LAE102

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE120

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laekna's LAE120 IND Approved by FDA for Advanced Solid Tumors

                            Details : LAE120 is an novel USP1 inhibitor drug candidate, being investigated for the treatment of advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : LAE120

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE102

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            China-Based Biotech Laekna Teams up with Lilly to Develop Muscle Preserving Obesity Drug

                            Details : The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) antagonistic monoclonal antibody (mAb) for muscle-preserving weight loss in Obesity.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 20, 2024

                            Lead Product(s) : LAE102

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE102

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate LAE102 in Healthy and Overweight/Obese Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : LAE102

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laekna Gets FDA Approval for Phase III Protocol of LAE002 Plus LAE001 in Prostate Cancer

                            Details : LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 inhibitor) is being developed in patients with mCRPC following standard of care (SOC) treatment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2024

                            Lead Product(s) : LAE001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afuresertib,Sintilimab,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laekna Therapeutics and Innovent Biologics obtain IND Approval for Combination Therapy in Patients With Specif...

                            Details : LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 01, 2022

                            Lead Product(s) : Afuresertib,Sintilimab,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C Afuresertib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Mass Balance and Biotransformation Study of [14C]Afuresertib

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            August 05, 2022

                            Lead Product(s) : 14-C Afuresertib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LAE005

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 25, 2022

                            Lead Product(s) : LAE005

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afuresertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Afuresertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Laekna Therapeutics

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sintilimab,Afuresertib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for ...

                            Details : The combination therapy consists of Laekna’s afuresertib (LAE002), a highly selective ATP competitive AKT inhibitor in clinical trials with favorable efficacy and safety profile, and Innovent’s PD-1 inhibitor sintilimab (TYVYT), which has been approv...

                            Product Name : Tyvyt

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 08, 2022

                            Lead Product(s) : Sintilimab,Afuresertib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth